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Abstract
Purpose—Musculoskeletal events (MEs) resulting from breast cancer treatment can significantly 
interfere with the quality of life (QOL) of older adults. We evaluated the incidence of MEs in 
women 65 years and older who had surgery and adjuvant chemotherapy for breast cancer, and the 
impact of treatment on MEs and arm function.
Patients and Methods—Patient-reported data in Alliance/CALGB 49907 were collected using 
the EORTC QLQ-BR23 and physician-reported adverse events (AEs) to characterize self-reported 
MEs and incidence of lymphedema. EORTC QLQ-BR23 items related to musculoskeletal events 
were analyzed in this study and data collected at study entry (post-operative) and 12 and 24 
months post entry.
Results—Lymphedema, arm function and ME data were available for 321 patients. One or more 
MEs were reported by 87% (median number=3) and 64% (median number=1) of patients post-
operatively and at 24 months. At 24 months 2% had persistence of six MEs. Seventy-four percent 
experienced at least ≥3/6 types of MEs over the 24-month period. Detection of lymphedema at any 
time during the study was noted in 7.5% of the patients and appeared to be associated with type of 
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chemotherapy given: CMF 16.4%, capecitabine 5.8% and AC 4%. Mastectomy and axillary node 
dissection were associated with the most MEs. LROM correlated with poorer arm function at all 
time periods.
Conclusion—Potentially debilitating MEs occur in three-fourths of elderly women undergoing 
standard therapy for breast cancer. Emphasis should be placed on prevention, identification and 
treatment of these MEs to improve QOL.
Keywords
Breast Cancer; Elderly; Musculoskeletal Events; Lymphedema
Introduction
Musculoskeletal symptoms in older patients treated for potentially curable breast cancer 
occur frequently, but we have little data on self-reported symptoms and their effects on 
function and quality of life. This analysis seeks to address these gaps. Common signs and 
symptoms include lymphedema[1, 2], self-reported arm or hand swelling[3], breast pain 
[4, 5], breast sensitivity[5, 6], pain in the arm/shoulder[3] and limitations in range of motion 
(LROM)[3, 6]. The incidences of these symptoms vary and depend on the type of surgery 
[1, 2, 7], receipt of radiation therapy [1, 2], whether chemotherapy was administered, the type 
of chemotherapy [7, 8, 9] and whether patients received aromatase inhibitors.
Lymphedema is of major concern with a meta-analysis of 72 studies showing a 17% risk of 
lymphedema after therapy [10]. At least 20% of women who receive therapy for breast 
cancer experience arm/shoulder pain and 66% experience breast/chest wall pain [5, 6]. A 
survey of patients of all ages at varying time intervals from original therapy revealed 
persistent operative site pain in 35% of 730 patients who underwent breast-conserving 
surgery (BCS) versus 30% who underwent mastectomy. Persistent arm swelling was self-
reported in 14% who underwent BCS and 26% who underwent mastectomy, and LROM was 
reported in 32% having BCS versus 47% with mastectomy [7].
In older women, musculoskeletal problems during and after treatment might have more 
profound effects on physical function and quality of life (QOL) than in younger women and 
such complications could impact an individual’s ability to live independently. Cancer and 
Leukemia Group B (CALGB)/Alliance trial 49907 was a prospective randomized adjuvant 
trial of standard chemotherapy (doxorubicin and cyclophosphamide [AC] or 
cyclophosphamide, methotrexate, and fluorouracil [CMF]) versus capecitabine in women 65 
and older with Stage I to III breast cancer [11]. This study provides a unique opportunity for 
the prospective analysis of LE and self-reported musculoskeletal events and their effect on 
function and quality of life in this older population of breast cancer patients.
Methods
Alliance study 171302 is a secondary analysis of CALGB/Alliance 49907, the details of 
which have been previously published [11]. Three hundred twenty-one of the CALGB 49907 
patients were also enrolled in a QOL companion trial and as previously described were quite 
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similar in demographic and other characteristics to the overall group; professionally-
assessed lymphedema and patient self-assessed QOL data form the basis of this analysis 
[12]. For this study we matched the lymphedema adverse event (AE) data with the 321 
patients who provided QOL data. Each participant signed an IRB-approved, protocol-
specific informed consent in accordance with federal and institutional guidelines.
Lymphedema AE data were graded per Common Toxicity Criteria version 2 [13] during 
follow-up visits with the physician and the maximum physician-reported lymphedema grade 
experienced by each patient was recorded. Grade 0 Lymphedema indicates no lymphedema. 
Grade 1 indicates mild lymphedema and grade 2 indicates moderate lymphedema requiring 
compression. Six patient-reported musculoskeletal events (MEs) from the EORTC QLQ-
BR23 were utilized in this study: 1) pain in the arm/shoulder, 2) arm/hand swelling, 3) 
difficulty in raising arm or moving it sideways (limited range of motion, LROM), 4) breast 
pain in the affected breast, 5) breast swelling in the affected breast, and 6) oversensitivity in 
the affected breast. Patients reported on severity of these symptoms with the following 
descriptors: 1) not at all, 2) a little, 3) quite a bit, or 4) very much. Patients completed the 
assessments at three time points: study baseline (within 84 days following surgery), 12 
months from baseline, and 24 months from baseline. Patients with mastectomy and BCS 
completed the same questionnaires; we considered breast pain, breast sensitivity and breast 
swelling as referring to chest wall symptoms in patients who underwent mastectomy. One of 
the questions asked of participants at all 3 time points was their ability to lift a shopping bag 
or suitcase. We felt this question was one assessment of arm function.
We performed an analysis of physician-reported lymphedema and patient-reported data to 
determine the incidence of lymphedema and the six MEs experienced (i.e., pain in arms/
shoulder, arm/hand swelling, LROM, and pain, swelling, and sensitivity in the affected 
breast). The relationship of the most extensive surgery (BCS or mastectomy), axillary 
surgery, receipt of radiation, number of examined nodes, and chemotherapy type (AC, CMF, 
or capecitabine) to lymphedema and the six patient-reported MEs was also assessed. Data 
collection and statistical analyses were conducted by the Alliance Statistics and Data Center. 
Data quality was ensured by review of data by the Alliance Statistics and Data Center and by 
the study chairperson following Alliance policies. All analyses were based on the study 
database frozen on November 19, 2015.Patients were dichotomized for each of the seven 
endpoints described above, (lymphedema AE and the six MEs) in two ways: (1) any event: 
at least one ≥ grade 1 lymphedema event (vs. no lymphedema events) or an answer of “a 
little” or worse (vs. “none”) for each of the six MEs and (2) severe: at least one ≥ grade 3 
lymphedema event (vs. <grade 3 lymphedema events) or an answer of “quite a bit” or “very 
much” (vs. “none” or “a little”) for each of the six MEs.
Patients who enrolled into Alliance/CALGB 49907 and who answered at least one of the six 
MEs listed above at baseline were included in these analyses (N=321). Although not all of 
the 321 patients provided answers for all six MEs being assessed (as noted in the figures and 
tables), all available data were analyzed for associations, which led to different sample sizes 
when comparing variables at a given time point.
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Chi‐squared tests [14] were used to determine if a given event happened at a higher or lower 
rate was associated with variables measured at baseline (most extensive surgery, axillary 
dissection, radiation, number of nodes examined, and chemotherapy type). These tests were 
performed at 3 time points: post-operative study entry and 12 and 24 months post study 
entry. Since any results will be viewed as hypothesis generating in general, all available data 
were used for each analysis and no adjustments were made for multiple comparisons.
Results
Of the 612 patients who participated in Alliance/CALGB 49907, both self-reported ME 
outcomes and physician-reported lymphedema (LE) data were available for 321 patients. 
These same patients also answered the question of whether or not they could lift a shopping 
bag or suitcase. The mean age was 72 years and 87% were Caucasian. Fifty-five percent 
underwent mastectomy and 45% BCS. Twenty percent had only a sentinel lymph node 
(SLN) biopsy and 80% had an axillary lymph node dissection (ALND). Fifty-four percent 
received radiation therapy (RT) and per protocol all received chemotherapy (48% 
capecitabine, 31% AC and 21% CMF) [Table 1].
Eight-seven percent had at least one self-reported ME at study baseline (within 84 days post-
operative) and the median number of MEs at baseline was 3. By 12 months, 72% had 
persistence of at least one ME symptom and 64% had at least one lingering ME symptom at 
24 months [Table 2].
Over this same 24-month period, 7.5% of these 321 women developed grade 1 or grade 2 LE 
[Table 3]. LE incidence was associated with type of chemotherapy received: CMF (13.4% 
grade 1 and 3.0% grade 2), capecitabine (4.5% grade 1 and 1.3% grade 2) and AC (4.0% 
grade 1 and 0% grade 2) [p=0.007]. There was no association between mastectomy or BCS 
and LE incidence (p=0.453) nor any association with receipt of RT or not (p=0.308) and 
lymphedema incidence. Performance of an ALND or not and removal of ≥ 8 ALNs was 
however associated with the development of LE (p=0.042 and p=0.023, respectively). If no 
ALND was performed, only 1.5% developed grade 1 LE but if an ALND was done, 7.4% 
developed grade1 LE and 1.6% grade 2 (p=0.042). If 8 or more ALN were removed, 8.5% 
developed grade 1 LE and 1.9% grade 2 [Table 3].
Patient-reported arm/hand swelling at any time point post-surgery was significantly related 
to health care professional reported LE with p values from <0.001 to 0.003. Despite that 
association, only about 20% of women who reported arm/hand swelling over the 24-month 
period of the study developed sufficient LE to be noted by a healthcare professional. 
Conversely, 80% of women reporting arm/hand swelling were not noted to have enough 
swelling by healthcare professionals to diagnose LE [Table 4]. There was little change in 
arm/hand swelling over time from post-operative baseline, 12 months, and 24 months: 22%, 
21%, and 20%, respectively [Figure 1]. Arm and hand swelling did not affect arm function 
(ability to lift a shopping bag or suitcase) at any of the measured periods (p=0.260, p=0.136, 
and p=0.060) [Table 5]. Presence of lymphedema did not affect arm function either 
(p=0.716) [Data not shown].
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Limited range of motion as defined by difficulty in raising arm or moving it sideways did 
interfere with arm function at all measured time intervals: post-operative baseline p<0.001; 
12 months p=0.002; and 24 months p<0.001. Limited range of motion fell from 51% at 
baseline to 31% at 12 months and 21% by 24 months [Figure 1]. Breast sensitivity interfered 
with arm function in the post-operative (p=0.004) and 12-month (p=0.038) periods but 
resolved by 24 months (p=0.164). Breast sensitivity was present in 59% of women post-
operatively and declined to 40% at 12 months but persisted in 31% at 24 months [Figure 1]. 
Breast swelling also interfered with arm function at 12 months (p=0.018) but surprisingly 
did not interfere in the post-operative or 24-month period: p=0.352 and p=0.343. Breast 
swelling was present in 46% of participants in the post-operative period and dropped to 12% 
by 12 months and 10% by 24 months [Figure 1]. Arm and shoulder pain significantly 
interfered with arm function at all three measured intervals: p=0.078 post-operatively, 
p=0.005 at 12 months, and p=0.001 at 24 months. Arm and shoulder pain was seen in 63% 
at baseline, 49% at 12 months and 43% at 24 months [Figure 1]. Women with this post-
operative arm/shoulder pain also experienced significant breast pain with an incidence of 
57% at 12 months and 44% at 24 months (p<0.001 and p=0.002) respectively (Appendix 
Table 7). Breast pain only interfered with arm function in the post-operative period 
(p<0.001). Similarly breast pain was also present at 59% at baseline, 47% at 12 months and 
37% at 24 months.
Those that underwent an axillary dissection or had ≥ 8 axillary lymph nodes removed had an 
increased risk of arm/shoulder pain in the post-operative period with a 43% incidence 
(p<0.001) and 71% incidence (p<0.001) respectively. This association resolved by 12 
months (Appendix Table 6).
Discussion
This study in older women with early stage breast cancer with prospectively collected data 
on professionally assessed lymphedema and self-reported musculoskeletal events is one of 
the few to address these complications in this age group, to evaluate these symptoms over 
time, and to correlate these symptom changes with function. The persistence of self-reported 
arm/hand swelling, limited range of motion and arm/shoulder pain at 24 months in a quarter 
or more of these older women is substantial and threatens their ability to live independently. 
LE is a major complication of surgery and radiation and our physician-reported LE 
incidence of 7.5% at any time over 24 months compared poorly to the incidence of patient-
reported post-operative arm/hand swelling of 20% at 24 months. This discrepancy confirms 
current literature that shows that the incidence of treatment side-effects is higher when 
patient-reported compared to provider-reported, and may explain the large variability in the 
incidence of lymphedema that has been previously reported (0-56%) [15]. A recent review 
showed that patient-reported outcomes were indeed more accurate than provider adverse 
event reporting [16]. Part of the difference may be explained by our study’s reliance on 
provider and not volumetric LE assessment, further underestimating true incidence.
Limited range of motion and arm/shoulder pain, as expected, interfered with arm function at 
all measured time intervals, while neither arm/hand swelling nor LE did. Our 63% incidence 
of arm/shoulder pain at baseline in older women is similar to another study that showed an 
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incidence of 60% in breast cancer survivors of all ages [17]. This latter study revealed a 67% 
incidence of decreased upper body strength while we found 60% of our patients had LROM 
and poor arm function (as defined by ability to lift a suitcase or shopping bag). Surprisingly, 
limited range of motion was not associated with lymphedema in our study [data not shown] 
in contradistinction to others [18]. For the elderly this may convert those living 
independently into those requiring assistance.
ALND and removal of ≥8 ALN as compared to breast-conserving surgery or mastectomy 
were associated with greater arm/hand swelling (see Appendix). Our findings regarding 
ALND versus not and removal of ≥8 ALN and their association with lymphedema, self-
reported arm/hand swelling, limited range of motion, breast pain/sensitivity, and pain in arm/
shoulder are similar to that seen in American College of Surgeons Oncology Group 
(Alliance) Z0011 [19] (ALND versus no ALND in women with invasive breast cancer and 
sentinel lymph node metastasis) and National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B-32 [20, 21] (SLN versus ALND in clinically node negative breast cancer). For 
older women, our data and that of others suggest that the surgical approach of choice, if 
possible, is a lumpectomy and sentinel lymph node (SLN) biopsy [22].
Breast/chest wall swelling was commonly reported post-operatively but almost completely 
resolved by 24 months. It was more commonly reported in patients receiving radiation 
treatment, as was breast swelling and breast sensitivity, but this association was lost by 24 
months. These findings may represent lymphedema of the breast and their resolution with 
time should be reassuring to clinicians and older women with these symptoms. The 
incidence of breast or chest wall pain in our elderly patients post-operatively, at 12 months, 
and at 24 months of 59%, 47% and 36%, respectively, was somewhat dissimilar to an 
analysis in breast cancer patients of all ages of 68% at 6 months6 and 66% at 12 months [23], 
and to another analysis that revealed persistent pain in 33% at 12 months [5]. Our data and 
that of others confirm that pain diminishes significantly over time. We also found that post-
operative pain in the arm/shoulder was highly associated with continuing breast/chest wall 
pain and was increased with more extensive axillary surgery (data not shown). Limiting 
axillary surgery to sentinel lymph node biopsy or omitting it unless it will change treatment 
planning or outcomes, should help minimize these symptoms.
This study has several limitations. All patients were in good health and capable of 
participating in a clinical trial; therefore, these patients may differ from other older early 
stage breast cancer patients in the general population and our findings might underestimate 
the true frequency of musculoskeletal symptoms. Moreover, only one-half of the study 
population participated in the QOL portion of this study and not all ME data were available 
for each time point. We did not have baseline data on musculoskeletal events prior to 
surgery, nor what interventions or medications were implemented for these symptoms either 
before or after surgery and whether they affected the improvement in symptoms that were 
noted over time. Conversely, this is one of the few studies that prospectively captured these 
LE and ME complications in elderly patients on a clinical trial.
Overall, our data are reassuring and suggest that the frequency of major musculoskeletal 
symptoms in an older patient population participating in a clinical trial is substantial but 
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dramatically decreases with time. However, for many patients these symptoms are quite 
bothersome and affect quality of life. Oncologists should query older patients concerning 
musculoskeletal symptoms and refer patients for interventions when appropriate. In addition, 
these data should be shared with patients and families to optimize treatment planning.
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250 (77.9%) 56 (17.4%) 11 (3.4%) 4 (1.2%)





49 (73.1%) 15 (22.4%) 2 (3.0%) 1 (1.5%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=99)
78 (78.8%) 15 (15.2%) 4 (4.0%) 2 (2.0%)
 Capecitabine (N=155) 123 (79.4%) 26 (16.8%) 5 (3.2%) 1 (0.6%)
Vs Most Extensive Surgery 
(N=319)
0.621 0.359
 Breast Conserving 
Surgery (N=143)
113 (79.0%) 25 (17.5%) 4 (2.8%) 1 (0.7%)
 Full Mastectomy (N=176) 135 (76.7%) 31 (17.6%) 7 (4.0%) 3 (1.7%)
Vs Axillary Dissection 
(N=321)
<0.001 0.046
 No (N=65) 62 (95.4%) 3 (4.6%) 0 (0%) 0 (0%)
 Yes (N=256) 188 (73.4%) 53 (20.7%) 11 (4.3%) 4 (1.6%)
Vs RT (N=300) 0.570 0.789
 No (N=139) 110 (79.1%) 23 (16.6%) 4 (2.9%) 2 (1.4%)
 Yes (N=161) 123 (76.4%) 30 (18.6%) 6 (3.7%) 2 (1.2%)
Vs Number of Nodes 
Examined (N=314)
<0.001 0.083
 0-3 (N=49) 45 (91.8%) 4 (8.2%) 0 (0%) 0 (0%)
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 4-7 (N=53) 49 (92.5%) 3 (5.7%) 1 (1.9%) 0 (0%)




205 (79.2%) 38 (14.7%) 12 (4.6%) 4 (1.5%)





43 (79.6%) 9 (16.7%) 2 (3.7%) 0 (0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
64 (78.1%) 10 (12.2%) 6 (7.3%) 2 (2.4%)
 Capecitabine (N=123) 98 (79.7%) 19 (15.4%) 4 (3.3%) 2 (1.6%)
Vs Most Extensive Surgery 
(N=257)
0.968 0.929
 Breast Conserving 
Surgery (N=117)
93 (79.5%) 17 (14.5%) 5 (4.3%) 2 (1.7%)
 Full Mastectomy (N=140) 111 (79.3%) 20 (14.3%) 7 (5.0%) 2 (1.4%)
Vs Axillary Dissection 
(N=259)
0.320 0.628
 No (N=56) 47 (83.9%) 5 (8.9%) 3 (5.4%) 1 (1.8%)
 Yes (N=203) 158 (77.8%) 33 (16.3%) 9 (4.4%) 3 (1.5%)
Vs RT (N=245) 0.368 0.415
 No (N=109) 90 (82.6%) 14 (12.8%) 5 (4.6%) 0 (0%)
 Yes (N=136) 106 (77.9%) 21 (15.4%) 6 (4.4%) 3 (2.2%)
Vs Number of Nodes 
Examined (N=254)
0.479 0.582
 0-3 (N=44) 37 (84.1%) 4 (9.1%) 3 (6.8%) 0 (0%)
 4-7 (N=39) 32 (82.1%) 3 (7.7%) 1 (2.6%) 3 (7.7%)




193 (80.4%) 38 (15.8%) 8 (3.3%) 1 (0.4%)





36 (73.5%) 9 (18.4%) 3 (6.1%) 1 (2.0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=83)
64 (77.1%) 17 (20.5%) 2 (2.4%) 0 (0%)
 Capecitabine (N=108) 93 (86.1%) 12 (11.1%) 3 (2.8%) 0 (0%)
Vs Most Extensive Surgery 
(N=238)
0.202 0.039
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 Breast Conserving 
Surgery (N=108)
91 (84.3%) 16 (14.8%) 1 (0.9%) 0 (0%)
 Full Mastectomy (N=130) 101 (77.7%) 21 (16.2%) 7 (5.3%) 1 (0.8%)
Vs Axillary Dissection 
(N=240)
0.209 0.489
 No (N=52) 45 (86.5%) 6 (11.5%) 1 (1.9%) 0 (0%)
 Yes (N=188) 148 (77.7%) 32 (17.0%) 7 (3.7%) 1 (0.5%)
Vs RT (N=226) 0.522 0.833
 No (N=100) 82 (82.0%) 14 (14.0%) 4 (4.0%) 0 (0%)
 Yes (N=126) 99 (78.6%) 23 (18.3%) 3 (2.4%) 1 (0.8%)
Vs Number of Nodes 
Examined (N=236)
0.079 0.406
 0-3 (N=41) 38 (92.7%) 2 (4.9%) 1 (2.4%) 0 (0%)
 4-7 (N=39) 31 (79.5%) 5 (12.8%) 2 (5.1%) 1 (2.6%)
 8+ (N=156) 120 (76.9%) 31 (19.9%) 5 (3.2%) 0 (0%)
Table 2
Limited Range of Motion






Overall LROM (N=320) 157 (49.1%) 125 (39.1%) 31 (9.7%) 7 (2.2%)





33 (49.3%) 28 (41.8%) 5 (7.5%) 1 (1.5%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=99)
50 (50.5%) 36 (36.4%) 11 (11.1%) 2 (2.0%)
 Capecitabine (N=154) 74 (48.1%) 61 (39.6%) 15 (9.7%) 4 (2.6%)
Vs Most Extensive Surgery 
(N=318)
0.034 0.480
 Breast Conserving 
Surgery (N=143)
80 (55.9%) 48 (33.6%) 14 (9.8%) 1 (0.7%)
 Full Mastectomy (N=175) 77 (44.0%) 75 (42.9%) 17 (9.7%) 6 (3.4%)
Vs Axillary Dissection 
(N=320)
<0.001 0.466
 No (N=65) 48 (73.8%) 11 (16.9%) 6 (9.2%) 0 (0%)
 Yes (N=255) 109 (42.7%) 114 (44.7%) 25 (9.8%) 7 (2.7%)
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Vs RT (N=299) 0.668 0.938
 No (N=138) 66 (47.8%) 56 (40.6%) 14 (10.1%) 2 (1.4%)
 Yes (N=161) 81 (50.3%) 61 (37.9%) 16 (9.9%) 3 (1.9%)
Vs Number of Nodes 
Examined (N=313)
<0.001 0.871
 0-3 (N=49) 35 (71.4%) 9 (18.4%) 5 (10.2%) 0 (0%)
 4-7 (N=53) 32 (60.4%) 15 (28.3%) 6 (11.3%) 0 (0%)
 8+ (N=211) 85 (40.3%) 99 (46.9%) 20 (9.5%) 7 (3.3%)
AT 12 MONTHS
Overall LROM (N=259) 179 (69.1%) 63 (24.3%) 14 (5.4%) 3 (1.2%)





36 (66.7%) 15 (27.8%) 2 (3.7%) 1 (1.9%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
59 (72.0%) 19 (23.2%) 4 (4.9%) 0 (0%)
 Capecitabine (N=123) 84 (68.3%) 29 (23.6%) 8 (6.5%) 2 (1.6%)
Vs Most Extensive Surgery 
(N=257)
0.339 0.417
 Breast Conserving 
Surgery (N=117)
85 (72.6%) 26 (22.2%) 5 (4.3%) 1 (0.9%)
 Full Mastectomy (N=140) 94 (67.1%) 35 (25.0%) 9 (6.4%) 2 (1.4%)
Vs Axillary Dissection 
(N=259)
0.160 0.730
 No (N=56) 43 (76.8%) 9 (16.1%) 4 (7.1%) 0 (0%)
 Yes (N=203) 136 (67.0%) 54 (26.6%) 10 (4.9%) 3 (1.4%)
Vs RT (N=245) 0.796 0.467
 No (N=109) 77 (70.6%) 26 (23.9%) 5 (4.6%) 1 (0.9%)
 Yes (N=136) 94 (69.1%) 32 (23.5%) 8 (5.9%) 2 (1.5%)
Vs Number of Nodes 
Examined (N=254)
0.536 0.904
 0-3 (N=44) 33 (75.0%) 9 (20.5%) 2 (4.5%) 0 (0%)
 4-7 (N=39) 25 (64.1%) 11 (28.2%) 3 (7.7%) 0 (0%)
 8+ (N=171) 116 (67.8%) 43 (25.1%) 9 (5.3%) 3 (1.8%)
AT 24 MONTHS
Overall LROM (N=240) 190 (79.1%) 39 (16.3%) 8 (3.3%) 3 (1.3%)





35 (71.4%) 10 (20.4%) 3 (6.1%) 1 (2.0%)
Hopkins et al. Page 10


















 AC (Doxorubicin and 
Cyclophosphamide) (N=83)
63 (75.9%) 15 (18.1%) 4 (4.8%) 1 (1.2%)
 Capecitabine (N=108) 92 (85.2%) 14 (13.0%) 1 (0.9%) 1 (0.9%)
Vs Most Extensive Surgery 
(N=238)
0.028 0.234
 Breast Conserving 
Surgery (N=108)
93 (86.1%) 12 (11.1%) 3 (2.8%) 0 (0%)
 Full Mastectomy (N=130) 97 (74.6%) 25 (19.2%) 5 (3.8%) 3 (2.3%)
Vs Axillary Dissection 
(N=240)
0.748 0.862
 No (N=52) 42 (80.8%) 8 (15.4%) 2 (3.8%) 0 (0%)
 Yes (N=188) 148 (78.7%) 31 (16.5%) 6 (3.2%) 3 (1.6%)
Vs RT (N=226) 0.691 0.292
 No (N=100) 78 (78.0%) 19 (19.0%) 3 (3.0%) 0 (0%)
 Yes (N=126) 101 (80.2%) 18 (14.3%) 5 (4.0%) 2 (1.6%)
Vs Number of Nodes 
Examined (N=236)
0.465 0.832
 0-3 (N=41) 34 (82.9%) 6 (14.6%) 1 (2.4%) 0 (0%)
 4-7 (N=39) 33 (84.6%) 4 (10.3%) 0 (0%) 2 (5.1%)
 8+ (N=156) 120 (76.9%) 28 (18.0%) 7 (4.5%) 1 (0.6%)
Table 3
Breast Swelling






Overall Breast Swelling 
(N=320)
172 (53.8%) 121 (37.8%) 19 (5.9%) 8 (2.5%)





33 (50.0%) 29 (43.9%) 2 (3.0%) 2 (3.0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=99)
49 (49.5%) 43 (43.4%) 4 (4.0%) 3 (3.0%)
 Capecitabine (N=155) 90 (58.1%) 49 (31.6%) 13 (8.4%) 3 (1.9%)
Vs Most Extensive Surgery 
(N=318)
0.981 0.395
 Breast Conserving 
Surgery (N=143)
77 (53.8%) 56 (39.2%) 6 (4.2%) 4 (2.8%)
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 Full Mastectomy (N=175) 94 (53.7%) 64 (36.6%) 13 (7.4%) 4 (2.3%)
Vs Axillary Dissection 
(N=320)
0.091 0.463
 No (N=65) 41 (63.1%) 20 (30.8%) 2 (3.1%) 2 (3.1%)
 Yes (N=255) 131 (51.4%) 101 (39.6%) 17 (6.7%) 6 (2.4%)
Vs RT (N=300) 0.029 0.507
 No (N=139) 84 (60.4%) 45 (32.4%) 9 (6.5%) 1 (0.7%)
 Yes (N=161) 77 (47.8%) 69 (42.9%) 9 (5.6%) 6 (3.7%)
Vs Number of Nodes 
Examined (N=313)
0.065 0.562
 0-3 (N=49) 33 (67.3%) 13 (26.5%) 1 (2.0%) 2 (4.1%)
 4-7 (N=53) 31 (58.5%) 19 (35.8%) 1 (1.9%) 2 (3.8%)
 8+ (N=211) 105 (49.8%) 86 (40.8%) 16 (7.6%) 4 (1.9%)
AT 12 MONTHS
Overall Breast Swelling 
(N=257)
225 (87.5%) 25 (9.7%) 5 (1.9%) 2 (0.8%)





48 (88.9%) 5 (9.3%) 0 (0%) 1 (1.9%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
73 (89.0%) 8 (9.8%) 1 (1.2%) 0 (0%)
 Capecitabine (N=121) 104 (86.0%) 12 (9.9%) 4 (3.3%) 1 (0.8%)
Vs Most Extensive Surgery 
(N=255)
0.329 0.028
 Breast Conserving 
Surgery (N=115)
98 (85.21%) 11 (9.6%) 5 (4.3%) 1 (0.9%)
 Full Mastectomy (N=140) 125 (89.3%) 14 (10.0%) 0 (0%) 1 (0.7%)
Vs Axillary Dissection 
(N=257)
0.076 0.691
 No (N=55) 52 (94.5%) 2 (3.6%) 1 (1.8%) 0 (0%)
 Yes (N=202) 173 (85.6%) 23 (11.4%) 4 (2.0%) 2 (1.0%)
Vs RT (N=243) 0.011 0.013
 No (N=109) 102 (93.6%) 7 (6.4%) 0 (0%) 0 (0%)
 Yes (N=134) 111 (82.8%) 16 (11.9%) 5 (3.7%) 2 (1.5%)
Vs Number of Nodes 
Examined (N=252)
0.097 0.172
 0-3 (N=43) 41 (95.3%) 1 (2.3%) 1 (2.3%) 0 (0%)
 4-7 (N=39) 31 (79.5%) 5 (12.8%) 1 (2.6%) 2 (5.1%)
 8+ (N=170) 148 (87.1%) 19 (11.2%) 3 (1.8%) 0 (0%)
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Overall Breast Swelling 
(N=240)
217 (90.4%) 21 (8.8%) 1 (0.4%) 1 (0.4%)





43 (87.8%) 5 (10.2%) 0 (0%) 1 (2.0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=83)
75 (90.4%) 7 (8.4%) 1 (1.2%) 0 (0%)
 Capecitabine (N=108) 99 (91.7%) 9 (8.3%) 0 (0%) 0 (0%)
Vs Most Extensive Surgery 
(N=238)
0.804 0.201
 Breast Conserving 
Surgery (N=108)
97 (89.8%) 11 (10.2%) 0 (0%) 0 (0%)
 Full Mastectomy (N=130) 118 (90.8%) 10 (7.7%) 1 (0.8%) 1 (0.8%)
Vs Axillary Dissection 
(N=240)
0.112 0.475
 No (N=52) 50 (96.2%) 2 (3.8%) 0 (0%) 0 (0%)
 Yes (N=188) 167 (88.8%) 19 (10.1%) 1 (0.5%) 1 (0.5%)
Vs RT (N=226) 0.551 0.919
 No (N=100) 92 (92.0%) 7 (7.0%) 1 (1.0%) 0 (0%)
 Yes (N=126) 113 (89.7%) 12 (9.5%) 0 (0%) 1 (0.8%)
Vs Number of Nodes 
Examined (N=236)
0.509 0.425
 0-3 (N=41) 39 (95.1%) 2 (4.9%) 0 (0%) 0 (0%)
 4-7 (N=39) 35 (89.7%) 3 (7.7%) 0 (0%) 1 (2.6%)
 8+ (N=156) 139 (89.1%) 16 (10.3%) 1 (0.6%) 0 (0%)
Table 4
Breast Sensitivity






Overall Breast Sensitivity 
(N=320)
132 (41.3%) 146 (45.6%) 33 (10.3%) 9 (2.8%)





20 (30.3%) 38 (57.6%) 6 (9.1%) 2 (3.0%)
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 AC (Doxorubicin and 
Cyclophosphamide) (N=99)
43 (43.4%) 46 (46.5%) 9 (9.1%) 1 (1.0%)
 Capecitabine (N=155) 69 (44.5%) 62 (40.0%) 18 (11.6%) 6 (3.9%)
Vs Most Extensive Surgery 
(N=318)
0.176 0.530
 Breast Conserving 
Surgery (N=143)
53 (37.1%) 73 (51.0%) 14 (9.8%) 3 (2.1%)
 Full Mastectomy (N=175) 78 (44.6%) 72 (41.1%) 19 (10.9%) 6 (3.4%)
Vs Axillary Dissection 
(N=320)
0.081 0.062
 No (N=65) 33 (50.8%) 28 (43.1%) 3 (4.6%) 1 (1.5%)
 Yes (N=255) 99 (38.8%) 118 (46.3%) 30 (11.8%) 8 (3.1%)
Vs RT (N=300) 0.019 0.051
 No (N=139) 67 (48.2%) 60 (43.2%) 9 (6.5%) 3 (2.2%)
 Yes (N=161) 56 (34.8%) 79 (49.1%) 22 (13.7%) 4 (2.5%)
Vs Number of Nodes 
Examined (N=313)
0.137 0.424
 0-3 (N=49) 23 (46.9%) 21 (42.9%) 4 (8.2%) 1 (2.0%)
 4-7 (N=53) 27 (50.9%) 21 (39.6%) 3 (5.7%) 2 (3.8%)
 8+ (N=211) 79 (37.4%) 100 (47.4%) 26 (12.3%) 6 (2.8%)
AT 12 MONTHS
Overall Breast Sensitivity 
(N=258)
154 (59.7%) 90 (34.9%) 11 (4.3%) 3 (1.2%)





24 (44.4%) 26 (48.2%) 2 (3.7%) 2 (3.7%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
57 (69.5%) 23 (28.1%) 2 (2.4%) 0 (0%)
 Capecitabine (N=122) 73 (59.8%) 41 (33.6%) 7 (5.7%) 1 (0.8%)
Vs Most Extensive Surgery 
(N=256)
<0.001 0.440
 Breast Conserving 
Surgery (N=117)
57 (48.7%) 55 (47.0%) 4 (3.4%) 1 (0.9%)
 Full Mastectomy (N=139) 96 (69.1%) 34 (24.5%) 7 (5.0%) 2 (1.4%)
Vs Axillary Dissection 
(N=258)
0.043 0.043
 No (N=56) 40 (71.4%) 16 (28.6%) 0 (0%) 0 (0%)
 Yes (N=202) 114 (56.4%) 74 (36.6%) 11 (5.4%) 3 (1.5%)
Vs RT (N=244) <0.001 0.643
 No (N=109) 84 (77.1%) 20 (18.3%) 5 (4.6%) 0 (0%)
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 Yes (N=135) 61 (45.2%) 66 (48.9%) 5 (3.7%) 3 (2.2%)
Vs Number of Nodes 
Examined (N=253)
0.725 0.201
 0-3 (N=44) 27 (61.4%) 17 (38.6%) 0 (0%) 0 (0%)
 4-7 (N=39) 25 (64.1%) 11 (28.2%) 1 (2.6%) 2 (5.1%)
 8+ (N=170) 98 (57.6%) 61 (35.9%) 10 (5.9%) 1 (0.6%)
AT 24 MONTHS
Overall Breast Sensitivity 
(N=239)
166 (69.5%) 62 (25.9%) 8 (3.3%) 3 (1.3%)





32 (65.3%) 15 (30.6%) 1 (2.0%) 1 (2.0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
52 (63.4%) 25 (30.5%) 3 (3.7%) 2 (2.4%)
 Capecitabine (N=108) 82 (75.9%) 22 (20.4%) 4 (3.7%) 0 (0%)
Vs Most Extensive Surgery 
(N=237)
0.320 0.103
 Breast Conserving 
Surgery (N=107)
78 (72.9%) 27 (25.2%) 2 (1.9%) 0 (0%)
 Full Mastectomy (N=130) 87 (66.9%) 35 (26.9%) 5 (3.8%) 3 (2.3%)
Vs Axillary Dissection 
(N=239)
0.003 0.077
 No (N=51) 44 (86.3%) 7 (13.7%) 0 (0%) 0 (0%)
 Yes (N=188) 122 (64.9%) 55 (29.3%) 8 (4.3%) 3 (1.6%)
Vs RT (N=225) 0.347 0.494
 No (N=100) 73 (73.0%) 24 (24.0%) 3 (3.0%) 0 (0%)
 Yes (N=125) 84 (67.2%) 365(28.0%) 3 (2.4%) 3 (2.4%)
Vs Number of Nodes 
Examined (N=235)
0.293 0.756
 0-3 (N=41) 29 (70.7%) 11 (26.8%) 1 (2.4%) 0 (0%)
 4-7 (N=38) 30 (79.0%) 6 (15.8%) 1 (2.6%) 1 (2.6%)
 8+ (N=156) 103 (66.0%) 45 (28.9%) 6 (3.8%) 2 (1.3%)
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Overall Breast Pain (N=318) 130 (40.9%) 165 (51.9%) 21 (6.6%) 2 (0.6%)





22 (33.8%) 38 (58.5%) 4 (6.2%) 1 (1.5%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=99)
40 (40.4%) 53 (53.5%) 5 (5.1%) 1 (1.0%)
 Capecitabine (N=154) 68 (44.2%) 74 (48.1%) 12 (7.8%) 0 (0%)
Vs Most Extensive Surgery 
(N=316)
0.031 0.540
 Breast Conserving 
Surgery (N=143)
49 (34.3%) 85 (59.4%) 9 (6.3%) 0 (0%)
 Full Mastectomy (N=173) 80 (46.2%) 79 (45.7%) 12 (6.9%) 2 (1.2%)
Vs Axillary Dissection 
(N=318)
0.210 0.147
 No (N=65) 31 (47.7%) 32 (49.2%) 2 (3.1%) 0 (0%)
 Yes (N=253) 99 (39.1%) 133 (52.6%) 19 (7.5%) 2 (0.8%)
Vs RT (N=298) 0.007 0.308
 No (N=137) 68 (49.6%) 62 (45.3%) 6 (4.4%) 1 (0.7%)
 Yes (N=161) 55 (34.2%) 93 (57.8%) 12 (7.5%) 1 (0.6%)
Vs Number of Nodes 
Examined (N=311)
0.846 0.038
 0-3 (N=49) 21 (42.9%) 27 (55.1%) 1 (2.0%) 0 (0%)
 4-7 (N=53) 23 (43.4%) 29 (54.7%) 0 (0%) 1 (1.9%)
 8+ (N=209) 83 (39.7%) 105 (50.2%) 20 (9.6%) 1 (0.5%)
AT 12 MONTHS
Overall Breast Pain (N=259) 137 (52.9%) 109 (42.1%) 8 (3.1%) 5 (1.9%)





21 (38.9%) 29 (53.7%) 2 (3.7%) 2 (3.7%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
48 (58.5%) 33 (40.2%) 0 (0%) 1 (1.2%)
 Capecitabine (N=123) 68 (55.3%) 47 (38.2%) 6 (4.9%) 2 (1.6%)
Vs Most Extensive Surgery 
(N=257)
0.006 0.234
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 Breast Conserving 
Surgery (N=117)
51 (43.6%) 58 (49.6%) 6 (5.1%) 2 (1.7%)
 Full Mastectomy (N=140) 85 (60.7%) 50 (35.7%) 2 (1.4%) 3 (2.1%)
Vs Axillary Dissection 
(N=259)
0.909 0.896
 No (N=56) 30 (53.6%) 23 (41.1%) 1 (1.8%) 2 (3.6%)
 Yes (N=203) 107 (52.7%) 86 (42.4%) 7 (3.4%) 3 (1.5%)
Vs RT (N=245) <0.001 0.006
 No (N=109) 74 (67.9%) 34 (31.8%) 1 (0.9%) 0 (0%)
 Yes (N=136) 55 (40.4%) 69 (50.7%) 7 (5.1%) 5 (3.7%)
Vs Number of Nodes 
Examined (N=254)
0.708 0.284
 0-3 (N=44) 22 (50.0%) 20 (45.5%) 1 (2.3%) 1 (2.2%)
 4-7 (N=39) 23 (59.0%) 12 (30.8%) 1 (2.6%) 3 (7.7%)
 8+ (N=171) 91 (53.2%) 73 (42.7%) 6 (3.5%) 1 (0.6%)
AT 24 MONTHS
Overall Breast Pain (N=240) 152 (63.3%) 78 (32.5%) 8 (3.3%) 2 (0.8%)





26 (53.1%) 20 (40.8%) 2 (4.1%) 1 (2.0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=83)
53 (63.9%) 27 (32.5%) 2 (2.4%) 1 (1.2%)
 Capecitabine (N=108) 73 (67.6%) 31 (28.7%) 4 (3.7%) 0 (0%)
Vs Most Extensive Surgery 
(N=238)
0.281 0.100
 Breast Conserving 
Surgery (N=108)
65 (60.2%) 41 (38.0%) 2 (1.9%) 0 (0%)
 Full Mastectomy (N=130) 87 (66.9%) 35 (26.9%) 6 (4.6%) 2 (1.5%)
Vs Axillary Dissection 
(N=240)
0.049 0.089
 No (N=52) 39 (75.0%) 13 (25.0%) 0 (0%) 0 (0%)
 Yes (N=188) 113 (60.1%) 65 (34.6%) 8 (4.3%) 2 (1.1%)
Vs RT (N=226) 0.032 0.990
 No (N=100) 71 (71.0%) 25 (25.0%) 4 (4.0%) 0 (0%)
 Yes (N=126) 72 (57.1%) 49 (38.9%) 3 (2.4%) 2 (1.6%)
Vs Number of Nodes 
Examined (N=236)
0.265 0.334
 0-3 (N=41) 24 (58.5%) 17 (41.5%) 0 (0%) 0 (0%)
 4-7 (N=39) 29 (74.4%) 8 (20.5%) 1 (2.6%) 1 (2.6%)
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 8+ (N=156) 96 (61.5%) 52 (33.3%) 7 (4.5%) 1 (0.6%)
Table 6
Arm/Shoulder Pain






Overall Arm/Shoulder Pain 
(N=321)
118 (36.8%) 148 (46.1%) 45 (14.0%) 10 (3.1%)





19 (28.4%) 34 (50.8%) 14 (20.9%) 0 (0%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=99)
36 (36.4%) 47 (47.5%) 14 (14.1%) 2 (2.0%)
 Capecitabine (N=155) 63 (40.6%) 67 (43.2%) 17 (11.0%) 8 (5.2%)
Vs Most Extensive Surgery 
(N=319)
0.834 0.276
 Breast Conserving 
Surgery (N=143)
52 (36.4%) 70 (49.0%) 17 (11.9%) 4 (2.8%)
 Full Mastectomy (N=176) 66 (37.5%) 76 (43.2%) 28 (15.9%) 6 (3.4%)
Vs Axillary Dissection 
(N=321)
<0.001 0.009
 No (N=65) 37 (56.9%) 24 (36.9%) 4 (6.2%) 0 (0%)
 Yes (N=256) 81 (31.6%) 124 (48.4%) 41 (16.0%) 10 (3.9%)
Vs RT (N=300) 0.112 0.397
 No (N=139) 59 (42.4%) 60 (43.2%) 15 (10.8%) 5 (3.6%)
 Yes (N=161) 54 (33.5%) 78 (48.4%) 25 (15.5%) 4 (2.5%)
Vs Number of Nodes 
Examined (N=314)
<0.001 0.087
 0-3 (N=49) 25 (51.0%) 18 (36.7%) 6 (12.2%) 0 (0%)
 4-7 (N=53) 28 (52.8%) 20 (37.7%) 5 (9.4%) 0 (0%)
 8+ (N=212) 62 (29.2%) 106 (50.0%) 34 (16.0%) 10 (4.7%)
AT 12 MONTHS
Overall Arm/Shoulder Pain 
(N=259)
133 (51.4%) 96 (37.1%) 22 (8.5%) 8 (3.1%)
Vs Arm (N=259) 0.514 0.274
 CMF 
(Cyclophosphamide, 
24 (44.4%) 24 (44.4%) 5 (9.3%) 1 (1.9%)
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 AC (Doxorubicin and 
Cyclophosphamide) (N=82)
43 (52.4%) 33 (40.2%) 5 (6.1%) 1 (1.2%)
 Capecitabine (N=123) 66 (53.7%) 39 (31.7%) 12 (9.8%) 6 (4.9%)
Vs Most Extensive Surgery 
(N=257)
0.523 0.798
 Breast Conserving 
Surgery (N=117)
58 (49.6%) 46 (39.3%) 9 (7.7%) 4 (3.4%)
 Full Mastectomy (N=140) 75 (53.6%) 48 (34.3%) 13 (9.3%) 4 (2.9%)
Vs Axillary Dissection 
(N=259)
0.327 0.475
 No (N=56) 32 (57.1%) 16 (28.6%) 6 (10.7%) 2 (3.6%)
 Yes (N=203) 101 (49.8%) 80 (39.4%) 16 (7.9%) 6 (3.0%)
Vs RT (N=245) 0.074 0.556
 No (N=109) 63 (57.8%) 35 (32.1%) 9 (8.3%) 2 (1.8%)
 Yes (N=136) 63 (46.3%) 56 (41.2%) 11 (8.1%) 6 (4.4%)
Vs Number of Nodes 
Examined (N=254)
0.741 0.878
 0-3 (N=44) 25 (56.8%) 13 (29.5%) 4 (9.1%) 2 (4.5%)
 4-7 (N=39) 20 (51.3%) 14 (35.9%) 5 (12.8%) 0 (0%)
 8+ (N=171) 86 (50.3%) 66 (38.6%) 13 (7.6%) 6 (3.5%)
AT 24 MONTHS
Overall Arm/Shoulder Pain 
(N=240)
136 (56.7%) 83 (34.6%) 16 (6.7%) 5 (2.1%)





24 (50.0%) 20 (40.8%) 3 (6.1%) 2 (4.1%)
 AC (Doxorubicin and 
Cyclophosphamide) (N=83)
42 (50.6%) 30 (36.1%) 9 (10.8%) 2 (2.4%)
 Capecitabine (N=108) 70 (64.8%) 33 (30.6%) 4 (3.7%) 1 (0.9%)
Vs Most Extensive Surgery 
(N=238)
0.851 0.149
 Breast Conserving 
Surgery (N=108)
61 (56.5%) 41 (38.0%) 5 (4.6%) 1 (0.9%)
 Full Mastectomy (N=130) 75 (57.7%) 41 (31.5%) 10 (7.7%) 4 (3.1%)
Vs Axillary Dissection 
(N=240)
0.883 0.049
 No (N=52) 29 (55.8%) 22 (42.3%) 1 (1.9%) 0 (0%)
 Yes (N=188) 107 (56.9%) 61 (32.4%) 15 (8.0%) 5 (2.7%)
Vs RT (N=226) 0.346 0.453
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 No (N=100) 61 (61.0%) 30 (30.0%) 9 (9.0%) 0 (0%)
 Yes (N=126) 69 (54.8%) 49 (38.9%) 4 (3.2%) 4 (3.2%)
Vs Number of Nodes 
Examined (N=236)
0.788 0.229
 0-3 (N=41) 25 (61.0%) 15 (36.6%) 1 (2.4%) 0 (0%)
 4-7 (N=39) 21 (53.9%) 15 (38.5%) 2 (5.1%) 1 (2.6%)
 8+ (N=156) 87 (55.8%) 52 (33.3%) 13 (8.3%) 4 (2.6%)
Table 7
Post Op Arm/Shoulder Pain versus Breast Pain
Breast Pain – 12 months post op p-value
Arm/Shoulder Pain at Post Op (N=259) <0.001
 Yes (N=161) 91 (56.5%)
 No (N=98) 31 (31.6%)
Breast Pain – 24 months post op
Arm/Shoulder Pain at Post Op (N=240) 0.002
 Yes (N=149) 66 (44.3%)
 No (N=91) 22 (24.2%)
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Severity of EORTC QLQ-BR23 musculoskeletal events at baseline, 12 months, and 24 
months in: arm/hand swelling (A), limited range of motion (B), breast swelling (C), breast 
sensitivity (D), breast pain, (E), and arm/shoulder pain (F).
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Table 1
Baseline Patient Characteristics
Characteristic Patients with Quality of Life information
Age (years) N=321
 Mean (SD) 72.0 (4.8)
 Age 65-69 129 (40.2%)
 Age 70-79 179 (55.8%)
 Age 80+ 13 (4.1%)
Gender
 Female 321 (100%)
Race N=320
 White 278 (86.9%)
 Black 35 (10.9%)
 Other 7 (2.2%)
Most Extensive Surgery N=319
 Breast Conservation Surgery 143 (44.8%)
 Mastectomy 176 (55.2%)
Axillary Dissection N=321
 Yes 256 (79.8%)
 No 65 (20.2%)
Radiation N=300
 Yes 161 (53.7%)
 No 139 (46.3%)
Number of Examined Nodes N=314
 Mean (SD) 11.8 (7.3)
 Range 0-32
Chemotherapy Type N=321
 AC (Doxorubicin and Cyclophosphamide) 99 (30.8%)
 CMF (Cyclophosphamide, Methotrexate and Fluorouracil) 67 (20.9%)
 Capecitabine 155 (48.3%)
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Table 2









Mean (Median) 3.0 (3) 1.7 (2) 1.6 (1)
None 43 (13.4%) 72 (27.8%) 86 (35.8%)
 1 31 (9.7%) 38 (14.7%) 40 (16.7%)
 2 50 (15.6%) 58 (22.4%) 46 (19.2%)
 3 68 (21.2%) 34 (13.1%) 39 (16.3%)
 4 52 (16.2%) 30 (11.6%) 13 (5.4%)
 5 44 (13.7%) 20 (7.7%) 12 (5.0%)
 6 33 (10.3%) 7 (2.7%) 4 (1.7%)
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Table 4
Lymphedema reported as an adverse event (AE) vs patient-reported swelling of arm and hand.




Arm/Hand Swelling at Post-operative (N=321) <0.001
 Yes 13 (18.3%) 58 (81.7%)
 No 11 (4.4%) 239 (95.6%)
Arm/Hand Swelling at 12 mo Post Op (N=259) 0.003
 Yes 10 (18.5%) 44 (81.5%)
 No 12 (5.9%) 193 (94.1%)
Arm/Hand Swelling at 24 mo Post Op (N=240) <0.001
 Yes 10 (21.3%) 37 (78.7%)
 No 6 (3.1%) 187 (96.9%)
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Table 5
Arm function versus musculoskeletal events over time*
Rates with symptom Post-operative 12 months 24 months
Vs LROM* p<0.001 p=0.002 p<0.001
 Poor Arm Function 111/186 (60%) 57/143 (39%) 38/133 (29%)
 Normal Arm Function 51/130 (39%) 24/113 (21%) 11/105 (10%)
Vs Breast Sensitivity p=0.004 p=0.038 p=0.164
 Poor Arm Function 122/186 (66%) 69/142 (46%) 45/133 (34%)
 Normal Arm Function 64/130 (49%) 38/113 (34%) 27/105 (26%)
Vs Breast Swelling p=0.352 p=0.018 p=0.343
 Poor Arm Function 90/186 (48%) 24/141 (17%) 15/133 (11%)
 Normal Arm Function 56/130 (43%) 8/113 (7%) 8/105 (8%)
Vs Arm/Shoulder Pain p=0.078 p=0.005 p=0.001
 Poor Arm Function 126/187 (67%) 81/143 (57%) 70/133 (53%)
 Normal Arm Function 75/130 (58%) 44/113 (39%) 33/105 (31%)
Vs Breast Pain p<0.001 p=0.266 p=0.065
 Poor Arm Function 126/186 (68%) 72/143 (50%) 56/133 (42%)
 Normal Arm Function 60/128 (47%) 49/113 (44%) 32/105 (30%)
Vs Arm/Hand Swelling P=0.260 p=0.136 p=0.060
 Poor Arm Function 46/187 (25%) 35/143 (24%) 32/133 (24%)
 Normal Arm Function 25/130 (19%) 19/113 (17%) 15/105 (14%)
*
For example, at the post-operative time point, patients with poor arm function at baseline had limited range of motion (LROM) 60% of the time 
compared to 39% for those with normal arm function
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